https://orcid.org/0000-0001-7141-4890
References
- Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8:315–26.
- Blanco C, Volkow ND. 2019. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 393(10182):1760–72. doi:https://doi.org/10.1016/S0140-6378(18)33078-2.
- Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP20-22-01-006. Rockville, MD: Substance Abuse and Mental Health Care Services Administration, 2020.
- Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8:315–26. doi:https://doi.org/10.1097/ADM.0000000000000045.
- Otuonye IS, Banken R, Kumar VM, Pearson SD. The effectiveness and value of extended-release opioid agonists and antagonists for addiction treatment of opioid use disorder: a summary from the institute for clinical and economic review’s new England comparative effectiveness public advisory council. J Managed Care Specialty Pharm. 2019;25(6):630–34. doi:https://doi.org/10.18553/jmcp.2019.25.6.630.
- Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2018;393(10173):778–90. doi:https://doi.org/10.1016/S0140-6736(18)32259-1.
- Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh Y-C, Learned SM, Mehra V, and Heidbreder C. Effects of monthly buprenorphine extended -release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2020;110:1–8.
- Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, et al. Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12 month longitudinal outcomes from RECOVER, an observational study. J Addict Med. 2020;14(5):e233. doi:https://doi.org/10.1097/ADM.0000000000000647.
- Wang L, Porte B, Maynard C, Evans G, Bryson C, Sun H, Gupta I, Lowy E, McDonell M, Frisbee K, et al. Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration. Med Care. 2013;51(4):368–73. doi:https://doi.org/10.1097/MLR.0b013e31827da95a.
- Ruiz JG, Priyadarshni S, Rahaman Z, Cabrera K, Dang S, Valencia WM, and Mintzer MJ. Validation of an automatically generated screening score for frailty: the care assessment need (CAN) score. BMC Geriatr. 2018;18(106). doi:https://doi.org/10.1186/s12877-018-0802-7.
- Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. 2021. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials. Clin Pharmacokinet. 60(4):527–40. doi:https://doi.org/10.1007/s40262-020-00957-0.